Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study

Autor: With, M. de, Knikman, J., Man, F.M. de, Lunenburg, C.A.T.C., Henricks, L.M., Kuilenburg, A.B.P. van, Maring, J.G., Staveren, M.C. van, Vries, N. de, Rosing, H., Beijnen, J.H., Pluim, D., Modak, A., Imholz, A.L.T., Schaik, R.H.N. van, Schellens, J.H.M., Gelderblom, H., Cats, A., Guchelaar, H.J., Mathijssen, R.H.J., Swen, J.J., Meulendijks, D.

Publikováno v: Clinical Pharmacology & Therapeutics, 112(1), 62-68. WILEY
Clinical Pharmacology and Therapeutics, 112(1), 62-68. Wiley-Blackwell
Clinical pharmacology and therapeutics, 112(1), 62-68. Wiley-Blackwell

In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe fluoropyrimidine-related toxicity. Extensively clinically validated DPYD genotyping tests are available to identify patients at risk of severe toxicity du

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5e872538b1e1ef4d8d5d9938c0f590e
http://hdl.handle.net/1887/3515269

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.

Autor: Meulendijks, D¹, Tomasoa, N B², Dewit, L², Smits, P H M³, Bakker, R³, van Velthuysen, M-L F⁴, Rosenberg, E H⁴, Beijnen, J H⁵, Schellens, J H M⁶, Cats, A⁷

Publikováno v: British Journal of Cancer. 4/14/2015, Vol. 112 Issue 8, p1358-1366. 9p. 4 Charts, 3 Graphs.

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.

Autor: Meulendijks, D¹, Dewit, L², Tomasoa, N B², van Tinteren, H³, Beijnen, J H⁴, Schellens, J H M⁵, Cats, A⁶

Publikováno v: British Journal of Cancer. 10/28/2014, Vol. 111 Issue 9, p1726-1733. 8p. 5 Charts, 2 Graphs.